News

China Shenghuo has posted a net income attributable to stockholders for the fourth quarter 2009 of $0.2m, compared with a net loss of $2.4m for the fourth quarter

Reportedly, MDV3100 demonstrated anti-tumor activity in patients with late-stage prostate cancer as evaluated by reductions in prostate specific antigen (PSA) levels, radiographic findings and circulating tumor cell (CTC)

Reportedly, four new business units will be created namely Primary Care, Multiple Sclerosis, Psychiatry/Neuroscience and respiratory/Transplant/Infectious Disease. The changes will be implemented from May 1 and impact approximately

BASF SE is is said to be considered the leading potential bidder, reported Dow Jones Newswires quoting some sources familiar with the news. According to Charles Cooley, CFO

OrbusNeich Medical noted that it has identified unlicensed use by Boston Scientific of certain technologies protected under US Patent No 7,682,384 B2. As the owner by assignment of

T-DM1 comprises ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeting antibody, trastuzumab, developed by Genentech, a wholly owned member of the Roche Group. T-DM1 is in global

Granisetron is expected to be made available in 0.1mg per ml and 1.0mg per ml single-dose vials, and 4.0mg per 4ml multi-dose vials. Sagent expects to begin marketing

Atlas Operations is conducting a voluntary recall after being informed by the FDA that lab analyses found that the products to contain Sulfoaildenafil, an analogue of Sildenafil, an

The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios’ innovative cancer metabolism research platform.